News

Introducing LiverSmart: A New AI Medical Device

Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance.

LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver. 

Read more

EASL Digital #NAFLDSummit 2021: Resonance Health presents, HepaFat-AI results equivalent to a conventional MRS technique

Resonance Health attended the EASL Digital NAFLD Summit 2021 on 16 – 17 September and participated with insights into developments in artificial intelligence-based approaches to NAFLD management using HepaFat-AI.

Read more

Appointment of GM - Global Sales & Marketing

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager - Global Sales & Marketing.

Read more

Resonance Health News - June 2021

Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities.

To read the newsletter please click here

Appointment of Chief Financial Officer & Company Secretary

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021. 

Read more

HepaFat-AI Receives CE Marking

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).

Read more